View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Theme
  2. Macro
  3. Covid-19
December 13, 2021updated 07 Jan 2022 5:46am

Coronavirus company news summary – AstraZeneca to supply antibody therapy to Singapore – South Korea to reduce Covid-19 booster interval amid rising cases

By Darcy Jimenez

AstraZeneca is set to supply Evusheld, a Covid-19 antibody combination therapy, to Singapore by the end of the year, Reuters has reported. The company has not specified the size of the shipment. The move comes after the US Food and Drug Administration granted emergency use of Evusheld for pre-exposure prevention of Covid-19. A combination of two monoclonal antibodies, tixagevimab and cilgavimab, Evusheld is designed to protect at-risk individuals with weak immunity.

South Korea has decided to reduce the interval for Covid-19 booster vaccines for all adults in a bid to contain rising infections in the country. The interval time will be trimmed from the current four to five months to three, Reuters reported, quoting officials. Previously, the government reduced the booster gap for individuals aged 60 and above to four months from six. Around 94% of the South Korean adults are fully vaccinated, with around 31% of eligible population receiving booster shots.

Australian Government has authorised Moderna’s Covid-19 vaccine as a recommended booster shot for individuals above 18 years of age. With this authorisation, Spikevax (Moderna) joins Comirnaty (Pfizer) as the preferred vaccines for the booster doses. Separately, the Australian Technical Advisory Group on Immunisation has updated its advice and reduced the time interval for the booster shot to five months after the second dose. Previously, the interval period was six months.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Pharmaceutical Technology